Article type: Case Report
Article
title: Carbamazepine-associated urinary incontinence: a case report and literature review
Journal: International
Journal of Medicine and Health Development
Year: 2019
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Carbamazepine (CBZ) is an
anticonvulsant approved for the management of many neurological and psychiatric
disorders. We present a case of an adult male with epilepsy who reported new
seizures, and the dose of CBZ administered was 1600 mg daily. CBZ dose was
increased to 1800 mg daily. The subject complained of urinary incontinence
without dysuria that started after the CBZ dose increase. It was associated
with urgency, hesitancy, dribbling of urine, and poor stream. Laboratory tests
were within normal limits. He admitted dry mouth, flushing, constipation, and
accommodation paralysis starting after CBZ increase. Assuming that these
symptoms were an adverse drug reaction, CBZ was withdrawn and valproate was
started. The individual had full recovery within four weeks. To the best of our
knowledge, only two case reports of similar nature are available, but this is
the first one to be reported with a young male adult.
Keywords: Carbamazepine, anticonvulsant, urinary incontinence
Full text
available at:
DOI
10.4103/ijmh.IJMH_25_19
Citation
Rissardo JP, Caprara AL. Carbamazepine-associated urinary incontinence: a case report and literature review. Int J Med Health Dev 2019;24:114-7
